Amarin Corp. PLC (AMRN) Shares Down 3%
Amarin Corp. PLC (NASDAQ:AMRN)’s share price traded down 3% during mid-day trading on Thursday . The stock traded as low as $2.95 and last traded at $3.22, with a volume of 7,052,162 shares traded. The stock had previously closed at $3.32.
Several equities analysts recently issued reports on the company. Zacks Investment Research upgraded Amarin Corp. PLC from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a research note on Thursday. Jefferies Group reaffirmed a “buy” rating and issued a $3.50 target price on shares of Amarin Corp. PLC in a research report on Thursday, July 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Amarin Corp. PLC in a research report on Monday, May 9th.
The company’s market cap is $604.97 million. The firm has a 50 day moving average of $2.33 and a 200 day moving average of $1.82.
Amarin Corp. PLC (NASDAQ:AMRN) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. The company earned $32.82 million during the quarter, compared to the consensus estimate of $29.97 million. The firm’s revenue was up 85.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.15) earnings per share. On average, equities research analysts anticipate that Amarin Corp. PLC will post ($0.57) EPS for the current fiscal year.
An institutional investor recently raised its position in Amarin Corp. PLC stock. OppenheimerFunds Inc. raised its stake in Amarin Corp. PLC (NASDAQ:AMRN) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,323,360 shares of the biopharmaceutical company’s stock after buying an additional 27,090 shares during the period. OppenheimerFunds Inc. owned about 2.90% of Amarin Corp. PLC worth $10,061,000 as of its most recent filing with the SEC.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.